SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Investing in Exponential Growth

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Paul H. Christiansen2/14/2020 12:13:53 PM
1 Recommendation

Recommended By
FUBHO

   of 965
 
Crispr'd Cells Show Promise in First US Human Safety Trial

It’s been over three years since US regulators greenlit the nation’s first in-human test of Crispr’s disease-fighting potential, more than three years of waiting to find out if the much-hyped gene-editing technique could be safely used to beat back tough-to-treat cancers. Today, researchers from the University of Pennsylvania and Stanford finally revealed the first published report describing the trial. The highly anticipated results showed that the procedure is both safe and feasible; the Crispr’d cells went where they were supposed to go and survived for longer than expected. They didn’t cure anyone’s cancer, but they didn’t kill anyone, either, which means the results hold significant promise for the future of Crispr-based medicines.

Read More - Wired
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext